Work Here?
About Synlab
Industries
Healthcare
Company Size
5,001-10,000
Company Stage
Acquired
Total Funding
$1.7B
Headquarters
Munich, Germany
Founded
1998
Overview
SYNLAB provides a comprehensive array of medical laboratory services aimed at supporting doctors, clinics, and patients. Their services include diagnostic testing that is both fast and reliable, ensuring high-quality results. Operating in 36 countries across four continents, SYNLAB stands out as the leading provider of laboratory services for human medicine in Europe. Unlike many competitors, SYNLAB's extensive network and established presence in multiple countries allow them to deliver consistent and efficient diagnostic services. The company's goal is to enhance healthcare by providing accurate and timely laboratory results that aid in patient diagnosis and treatment.
Simplify's Take
What believers are saying
- Labcorp's investment could enhance Synlab's diagnostic capabilities and market reach in Europe.
- Sale of Synlab España may increase operational efficiency in core markets.
- Cinven and Labcorp's involvement may provide capital for growth and innovation.
What critics are saying
- Recent ransomware attacks could damage Synlab's reputation and operational reliability.
- Sale of Synlab España to Eurofins may lead to increased competition in Iberia.
- Ongoing squeeze-out process may create internal uncertainties and affect stakeholder confidence.
What makes Synlab unique
- SYNLAB is the leader in European human medicine laboratory services.
- Operates in 36 countries across 4 continents, ensuring a broad market presence.
- Provides over 600 million laboratory tests annually, showcasing extensive operational capacity.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$1740M
Above
Industry Average
Funded Over
2 Rounds
Benefits
Wellness Program
Professional Development Budget
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↑ 1%2 year growth
↑ 0%March 24, 2025 -- International private equity firm Cinven has completed its previously announced sale of an indirect minority stake in SYNLAB, a leader in medical diagnostic services and specialty testing in Europe, to strategic investor Labcorp. Labcorp is a global leader of innovative and comprehensive laboratory services headquartered in the United States. Labcorp acquired the indirect minority stake through an intermediate holding company established to hold the investment with SYNLAB and is represented on the holding company board along with Cinven and the other co-investors. SYNLAB offers a full range of innovative and reliable medical diagnostic services to patients, practicing doctors, hospitals and clinics, governments and corporates. Operating in over 30 countries across four continents with more than 26,000 employees, including over 2,000 medical experts, SYNLAB performed approximately 600 million laboratory tests and achieved revenues of around €2.62 billion in 2024. The companies plan to explore possible opportunities in the future to bring Labcorp’s innovative specialty tests to markets in Europe, consider possible procurement collaborations, evaluate opportunities to support advances in clinical trials and enrolment and improve personalized care
GĂłmez-Acebo & Pombo has advised the Synlab Group, a leader in medical diagnostic services and specialized tests in Europe, in the sale of Synlab Spain to Eurofins Scientific (EUFI.PA).
Synlab is a medical diagnostic services and specialty testing provider.
EQS-News: SYNLAB AG / Key word(s): Miscellaneous/Squeeze OutCinven to Acquire Elliott’s Stake in SYNLAB AG, Squeeze-Out to Follow30.10.2024 / 07:32 CET/CESTThe issuer is solely responsible for the content of this announcement.Cinven to Acquire Elliott’s Stake in SYNLAB AG, Squeeze-Out to Follow Elliott to remain indirect minority shareholder in SYNLAB The Management Board of SYNLAB AG (“SYNLAB”) has been informed that international private equity firm Cinven has reached an agreement with funds advised by Elliott Advisors (UK) Limited (“Elliott”). Under this agreement, Cinven will acquire Elliott’s current direct minority stake of approximately 10% in SYNLAB. Elliott will become an indirect minority shareholder in SYNLAB, alongside existing shareholders Cinven, Labcorp (subject to regulatory approval), and Qatar Holding LLC. The transaction is subject to regulatory approvals and is expected to close in early 2025. The acquiring entity of Elliott’s shareholding will be Ephios Bidco GmbH (“Ephios Bidco”), an entity controlled by funds managed and/or advised by Cinven and the majority shareholder of SYNLAB AG. Ephios Bidco currently holds approximately 86% of the SYNLAB share capital
SYNLAB agrees to sell its Spanish business to Eurofins.
Synlab is Hiring for 5 Jobs on Simplify!
Find jobs on Simplify and start your career today
About Synlab
Industries
Healthcare
Company Size
5,001-10,000
Company Stage
Acquired
Total Funding
$1.7B
Headquarters
Munich, Germany
Founded
1998
Synlab is Hiring for 5 Jobs on Simplify!
Find jobs on Simplify and start your career today